Last reviewed · How we verify
Cicletanide (CICLETANINE)
Cicletanine works by interacting with a specific cellular pathway to produce its therapeutic effects.
Cicletanine, a small molecule drug in the cicletanine class, is a compound with unknown target and mechanism of action. Its commercial status is unclear, and it is not approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its potential therapeutic applications and safety profile. The compound's development history is also unclear, with unknown original developers and current owners.
At a glance
| Generic name | CICLETANINE |
|---|---|
| Drug class | cicletanine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Imagine your body's cells have a complex communication system. Cicletanine is thought to interfere with this system in a way that helps to treat certain conditions, although the exact details of how it does this are not yet fully understood.
Approved indications
Common side effects
Key clinical trials
- Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium (PHASE1,PHASE2)
- Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |